drugset / Trial / NCT02211950

Relative Bioavailability of BI 44847 in Different Ethnic Groups and Evaluation of Effect of Diet and Acarbose Coadministration on Bioavailability Following Oral Administration of 200 mg BI 44847 in Healthy Male Volunteers

NCT02211950

Phase 1 Completed 37 enrolled Boehringer Ingelheim
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The objectives were to investigate the relative bioavailability of BI 44847 in different racial groups (white, Asian, and African subjects) and to investigate the effect of different types of diet and acarbose coadministration on the bioavailability of BI 44847 in white subjects.

Timeline

Start
2008-10
Primary completion
2008-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Acarbose Unknown 100 mg
Subject BI 44847 Unknown 200 mg Oral

Indications

No indication recorded.